Featured Publications
Development of [89Zr]ZrDFO-amivantamab bispecific to EGFR and c-MET for PET imaging of triple-negative breast cancer
Cavaliere A, Sun S, Lee S, Bodner J, Li Z, Huang Y, Moores SL, Marquez-Nostra B. Development of [89Zr]ZrDFO-amivantamab bispecific to EGFR and c-MET for PET imaging of triple-negative breast cancer. European Journal Of Nuclear Medicine And Molecular Imaging 2020, 48: 383-394. PMID: 32770372, PMCID: PMC7855369, DOI: 10.1007/s00259-020-04978-6.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerEpidermal growth factor receptorPET/CTMDA-MB-468MDA-MB-231C-MetGrowth factor receptorIsotype controlBreast cancerMDA-MB-468 xenograftsBispecific antibodiesC-Met expression levelsHCC827 lung cancer cellsMono-targeted therapiesFactor receptorLevels of EGFROptimal imaging time pointC-Met expressionNovel bispecific antibodyStandard uptake valueRadioligand binding studiesExpression levelsLung cancer cellsMDA-MB-453Imaging time point
2017
Preclinical PET imaging of glycoprotein non-metastatic melanoma B in triple negative breast cancer: feasibility of an antibody-based companion diagnostic agent
Marquez-Nostra BV, Lee S, Laforest R, Vitale L, Nie X, Hyrc K, Keler T, Hawthorne T, Hoog J, Li S, Dehdashti F, X. C, Lapi SE. Preclinical PET imaging of glycoprotein non-metastatic melanoma B in triple negative breast cancer: feasibility of an antibody-based companion diagnostic agent. Oncotarget 2017, 5: 104303-104314. PMID: 29262642, PMCID: PMC5732808, DOI: 10.18632/oncotarget.22228.Peer-Reviewed Original ResearchTriple-negative breast cancerMDA-MB-468 xenograftsNegative breast cancerCDX-011Breast cancerMean SUVTumor uptakePatient-derived xenograft modelsDiagnostic imaging agentsGPNMB expressionMDA-MB-231 tumorsSelection of patientsTNBC cell linesImaging agentGlembatumumab vedotinPDX micePharmacologic propertiesPreclinical studiesXenograft modelTargeted treatmentMelanoma BDays p.Preclinical PET imagingUptake correlatesEffective dose